pegylated liposomal doxorubicin + cyclophosphamide

Pegylated liposomal doxorubicin + cyclophosphamide is a **combination chemotherapy regimen** used primarily in breast cancer (including metastatic breast cancer) and other malignancies. Pegylated liposomal doxorubicin is a liposome-encapsulated, polyethylene glycol (PEG)-coated formulation of doxorubicin that alters the pharmacokinetics of the parent drug, resulting in prolonged circulation time, enhanced tumor targeting, and a reduced risk of cardiotoxicity compared to conventional doxorubicin. Doxorubicin acts as a DNA intercalator and inhibitor of topoisomerase II, leading to DNA damage and apoptosis. Cyclophosphamide is an alkylating agent that crosslinks DNA, inhibiting cell division and triggering cell death. The combination is noted for maintaining antitumor efficacy with improved tolerability and reduced cardiac risk compared to traditional doxorubicin regimens[1][3][5][7].